Influence of patient characteristics on Helicobacter pylori eradication with Vonoprazan: A subgroup analysis of the pHalcon-HP trial

William D Chey; Francis Mégraud; Loren Laine; Neila Smith; Eckhard Leifke; Barbara Hunt; Colin W Howden

doi:10.1002/jgh3.70044

Influence of patient characteristics on Helicobacter pylori eradication with Vonoprazan: A subgroup analysis of the pHalcon-HP trial

JGH Open. 2024 Nov 15;8(11):e70044. doi: 10.1002/jgh3.70044. eCollection 2024 Nov.

Authors

William D Chey¹, Francis Mégraud², Loren Laine^{3

4}, Neila Smith⁵, Eckhard Leifke⁵, Barbara Hunt⁵, Colin W Howden⁶

Affiliations

¹ Gastroenterology and Nutrition Sciences, Division of Gastroenterology and Hepatology, Department of Internal Medicine Michigan Medicine Ann Arbor Michigan USA.
² Emeritus, INSERM U1312 University of Bordeaux Bordeaux France.
³ Medicine (Digestive Diseases) Yale School of Medicine New Haven Connecticut USA.
⁴ Attending Physician, VA Connecticut Healthcare System West Haven Connecticut USA.
⁵ Phathom Pharmaceuticals, Research and Development Buffalo Grove Illinois USA.
⁶ Emeritus, Department of Medicine University of Tennessee College of Medicine Memphis Tennessee USA.

Abstract

The efficacy of vonoprazan-based dual and triple therapy vs. lansoprazole-based triple therapy in the treatment of H. pylori infection was largely consistent regardless of age, sex, race, ethnicity, BMI, alcohol intake, smoking status, and study drug compliance.

Keywords: Helicobacter pylori; clinical trial; potassium competitive acid blockers; proton pump inhibitors; vonoprazan.